Logo image of MBX.CA

MICROBIX BIOSYSTEMS INC (MBX.CA) Stock Fundamental Analysis

TSX:MBX - Toronto Stock Exchange - CA59501P1045 - Common Stock - Currency: CAD

0.5  +0.02 (+4.17%)

Fundamental Rating

7

Overall MBX gets a fundamental rating of 7 out of 10. We evaluated MBX against 24 industry peers in the Biotechnology industry. MBX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. MBX is growing strongly while it also seems undervalued. This is an interesting combination This makes MBX very considerable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

MBX had positive earnings in the past year.
In the past year MBX had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: MBX reported negative net income in multiple years.
Of the past 5 years MBX 4 years had a positive operating cash flow.
MBX.CA Yearly Net Income VS EBIT VS OCF VS FCFMBX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M -6M

1.2 Ratios

With an excellent Return On Assets value of 9.24%, MBX belongs to the best of the industry, outperforming 90.00% of the companies in the same industry.
The Return On Equity of MBX (12.44%) is better than 95.00% of its industry peers.
MBX has a better Return On Invested Capital (8.43%) than 95.00% of its industry peers.
Industry RankSector Rank
ROA 9.24%
ROE 12.44%
ROIC 8.43%
ROA(3y)4.84%
ROA(5y)-2.84%
ROE(3y)6.48%
ROE(5y)-11.45%
ROIC(3y)N/A
ROIC(5y)N/A
MBX.CA Yearly ROA, ROE, ROICMBX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

MBX's Profit Margin of 13.86% is amongst the best of the industry. MBX outperforms 95.00% of its industry peers.
MBX's Profit Margin has improved in the last couple of years.
MBX's Operating Margin of 16.00% is amongst the best of the industry. MBX outperforms 100.00% of its industry peers.
MBX's Operating Margin has improved in the last couple of years.
MBX has a better Gross Margin (60.61%) than 85.00% of its industry peers.
In the last couple of years the Gross Margin of MBX has grown nicely.
Industry RankSector Rank
OM 16%
PM (TTM) 13.86%
GM 60.61%
OM growth 3Y-14.86%
OM growth 5Y15.81%
PM growth 3Y-7.25%
PM growth 5Y128.26%
GM growth 3Y0.68%
GM growth 5Y4.41%
MBX.CA Yearly Profit, Operating, Gross MarginsMBX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60

8

2. Health

2.1 Basic Checks

MBX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, MBX has less shares outstanding
Compared to 5 years ago, MBX has more shares outstanding
Compared to 1 year ago, MBX has an improved debt to assets ratio.
MBX.CA Yearly Shares OutstandingMBX.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
MBX.CA Yearly Total Debt VS Total AssetsMBX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

MBX has an Altman-Z score of 4.57. This indicates that MBX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 4.57, MBX belongs to the best of the industry, outperforming 90.00% of the companies in the same industry.
The Debt to FCF ratio of MBX is 2.62, which is a good value as it means it would take MBX, 2.62 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 2.62, MBX belongs to the best of the industry, outperforming 85.00% of the companies in the same industry.
A Debt/Equity ratio of 0.22 indicates that MBX is not too dependend on debt financing.
MBX has a Debt to Equity ratio of 0.22. This is in the better half of the industry: MBX outperforms 70.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF 2.62
Altman-Z 4.57
ROIC/WACC0.91
WACC9.23%
MBX.CA Yearly LT Debt VS Equity VS FCFMBX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

2.3 Liquidity

A Current Ratio of 7.15 indicates that MBX has no problem at all paying its short term obligations.
MBX's Current ratio of 7.15 is amongst the best of the industry. MBX outperforms 85.00% of its industry peers.
A Quick Ratio of 5.24 indicates that MBX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 5.24, MBX belongs to the best of the industry, outperforming 85.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.15
Quick Ratio 5.24
MBX.CA Yearly Current Assets VS Current LiabilitesMBX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

7

3. Growth

3.1 Past

MBX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 355.70%, which is quite impressive.
Measured over the past years, MBX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.58% on average per year.
MBX shows a strong growth in Revenue. In the last year, the Revenue has grown by 53.81%.
MBX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.62% yearly.
EPS 1Y (TTM)355.7%
EPS 3Y8.58%
EPS 5YN/A
EPS Q2Q%-67.9%
Revenue 1Y (TTM)53.81%
Revenue growth 3Y10.96%
Revenue growth 5Y13.62%
Sales Q2Q%47.6%

3.2 Future

MBX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 58.11% yearly.
Based on estimates for the next years, MBX will show a small growth in Revenue. The Revenue will grow by 6.53% on average per year.
EPS Next Y0%
EPS Next 2Y58.11%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-1.98%
Revenue Next 2Y6.53%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MBX.CA Yearly Revenue VS EstimatesMBX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M 25M
MBX.CA Yearly EPS VS EstimatesMBX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.02 -0.02 0.04

7

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 16.67, the valuation of MBX can be described as correct.
Based on the Price/Earnings ratio, MBX is valued cheaper than 90.00% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 28.35, MBX is valued a bit cheaper.
MBX is valuated rather expensively with a Price/Forward Earnings ratio of 24.75.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MBX indicates a rather cheap valuation: MBX is cheaper than 95.00% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of MBX to the average of the S&P500 Index (95.00), we can say MBX is valued rather cheaply.
Industry RankSector Rank
PE 16.67
Fwd PE 24.75
MBX.CA Price Earnings VS Forward Price EarningsMBX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

MBX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MBX is cheaper than 95.00% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MBX indicates a rather cheap valuation: MBX is cheaper than 90.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 27.56
EV/EBITDA 10.69
MBX.CA Per share dataMBX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.05 0.1 0.15 0.2

4.3 Compensation for Growth

MBX has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as MBX's earnings are expected to grow with 58.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y58.11%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

MBX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

MICROBIX BIOSYSTEMS INC

TSX:MBX (2/5/2025, 7:00:00 PM)

0.5

+0.02 (+4.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-19 2024-12-19/amc
Earnings (Next)02-12 2025-02-12
Inst Owners0.43%
Inst Owner ChangeN/A
Ins Owners14.72%
Ins Owner ChangeN/A
Market Cap67.27M
Analysts80
Price Target0.82 (64%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-15.12%
Revenue NY rev (3m)-15.12%
Valuation
Industry RankSector Rank
PE 16.67
Fwd PE 24.75
P/S 2.65
P/FCF 27.56
P/OCF 15.47
P/B 2.38
P/tB 2.79
EV/EBITDA 10.69
EPS(TTM)0.03
EY6%
EPS(NY)0.02
Fwd EY4.04%
FCF(TTM)0.02
FCFY3.63%
OCF(TTM)0.03
OCFY6.46%
SpS0.19
BVpS0.21
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 9.24%
ROE 12.44%
ROCE 11.71%
ROIC 8.43%
ROICexc 13.46%
ROICexgc 16.7%
OM 16%
PM (TTM) 13.86%
GM 60.61%
FCFM 9.61%
ROA(3y)4.84%
ROA(5y)-2.84%
ROE(3y)6.48%
ROE(5y)-11.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-16.73%
ROICexcg growth 5Y20.32%
ROICexc growth 3Y-19.11%
ROICexc growth 5Y24.01%
OM growth 3Y-14.86%
OM growth 5Y15.81%
PM growth 3Y-7.25%
PM growth 5Y128.26%
GM growth 3Y0.68%
GM growth 5Y4.41%
F-Score9
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF 2.62
Debt/EBITDA 1.08
Cap/Depr 118.23%
Cap/Sales 7.51%
Interest Coverage 250
Cash Conversion 76.6%
Profit Quality 69.34%
Current Ratio 7.15
Quick Ratio 5.24
Altman-Z 4.57
F-Score9
WACC9.23%
ROIC/WACC0.91
Cap/Depr(3y)133.78%
Cap/Depr(5y)133.99%
Cap/Sales(3y)8.11%
Cap/Sales(5y)7.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)355.7%
EPS 3Y8.58%
EPS 5YN/A
EPS Q2Q%-67.9%
EPS Next Y0%
EPS Next 2Y58.11%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)53.81%
Revenue growth 3Y10.96%
Revenue growth 5Y13.62%
Sales Q2Q%47.6%
Revenue Next Year-1.98%
Revenue Next 2Y6.53%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y248.29%
EBIT growth 3Y-5.54%
EBIT growth 5Y31.58%
EBIT Next Year-26.99%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y215.68%
FCF growth 3Y41.04%
FCF growth 5YN/A
OCF growth 1Y498.86%
OCF growth 3Y27.25%
OCF growth 5Y155.41%